MEDIA

Positive development in Nanexa’s patent litigation case

17 March, 2022
- Press Release
Download attachment

Nanexa AB today announced that the United States District Court for the District of Delaware in Nanexa AB v. VitriVax, Inc. C.A. No. 21-764 (JLH), today denied VitriVax’s motion to dismiss Nanexa’s complaint for patent infringement and denied as moot VitriVax’s motion to stay discovery. Furthermore, Nanexa’s motion to compel discovery was granted. Nanexa will continue to actively protect its valuable intellectual property rights related to its drug delivery system PharmaShell®.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
Erik Penser Bank is the company’s Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing parenteral drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Positive development in Nanexa’s patent litigation case